ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Forum: Aktien Thema: Hauptdiskussion

Da ist noch Luft nach oben

Tja, Zug schon abgefahren... heute über plus 102%

Denke mal da kann man noch profitieren

Nexscientific bei +60% 😱

https://seekingalpha.com/news/3703568-astrazeneca-signs-deal-with-netscientific-for-covid-19-test?utm_source=feed_news_all&utm_medium=referral

7 June 2021 Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.

🙋‍♂️

Es gibt keine deutsche News von Astra - wenn es dich interessiert, kannst mittels googletranslate übersetzen

😁

Hgfdftzzuuhhioo. 🤗

Deutsch Bitte

4 June 2021 AstraZeneca PLC announced today that the Board has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals, Inc. (Closing) and effective on the later of 1 August 2021 or the date of Closing, which is expected to take place in the third quarter of 2021, subject to receipt of certain regulatory approvals.

4 June 2021 Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).

3 June 2021 22:00 BST First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting Results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. The results will be presented during the plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on 6 June 2021 (abstract LBA#1) and were published today in The New England Journal of Medicine. An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.1,2

Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial